Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 10-CC-N061 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Background:
Objectives:
- To evaluate the primary and secondary motivations of healthy participants in research studies.
Eligibility:
- Individuals at least 18 years of age who are healthy volunteers in selected Pfizer Phase I clinical trials.
Design:
This healthy volunteer motivation study is a sub-study of Phase I drug development studies conducted by Pfizer International. The substudy is designed to evaluate the primary and secondary motivations of healthy participants in research studies, as well as the process by which participants decide to participate, including their consideration of any risks, benefits, compensation and other factors, and the relationship of these factors to cultural and sociodemographic variables. Data will be collected via self-administered surveys at 2 possible time points, 1) after going through the consent process at the beginning of participation in the primary study, and 2) towards the end of the study participation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Participants will be willing adults who have participated in an informed consent session for a designated Phase I study at a Pfizer CRU. Participants in New Haven and Singapore must be able to read and answer question in English and participants in Brussels must be able to read and answer questions either in English, French, or Flemish. Only adults (over 18 years old) who can provide their own consent will be included.
EXCLUSION CRITERIA:
Participants in Pfizer phase I studies who are unable or unwilling to complete the survey instruments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Christine Grady, M.D. | National Institutes of Health Clinical Center (CC) | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | 20892 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17891536 | Background | Almeida L, Azevedo B, Nunes T, Vaz-da-Silva M, Soares-da-Silva P. Why healthy subjects volunteer for phase I studies and how they perceive their participation? Eur J Clin Pharmacol. 2007 Nov;63(11):1085-94. doi: 10.1007/s00228-007-0368-3. Epub 2007 Sep 20. | |
| 2379528 | Background | Bigorra J, Banos JE. Weight of financial reward in the decision by medical students and experienced healthy volunteers to participate in clinical trials. Eur J Clin Pharmacol. 1990;38(5):443-6. doi: 10.1007/BF02336681. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Pfizer CRU |
| Brussels |
| Belgium |
| Pfizer CRU | Singapore | Singapore |
| 8062322 | Background | Cunny KA, Miller HW. Participation in clinical drug studies: motivations and barriers. Clin Ther. 1994 Mar-Apr;16(2):273-82; discussion 271-2. |